What is SeLux DX?
Founded in 2014 and headquartered in Charlestown, Massachusetts, SeLux DX is a pioneering force in the development of precision diagnostics for infectious diseases. The company specializes in creating high-throughput, rapid-response diagnostic solutions that provide clinicians with actionable data to improve patient outcomes. By integrating sophisticated engineering with clinical rigor, SeLux DX addresses the urgent demand for faster, more accurate pathogen identification and susceptibility testing. Its market position is defined by a focus on evidence-based innovation, bridging the gap between laboratory research and bedside application to combat the rising threat of antimicrobial resistance.
How much funding has SeLux DX raised?
SeLux DX has raised a total of $176.5M across 5 funding rounds:
Series A
$23.5M
Series B
$25M
Series C
$50M
Debt
$30M
Other Financing Round
$48M
Series A (2018): $23.5M, investors not publicly disclosed
Series B (2018): $25M led by Sands Capital Ventures and RA Capital Advisors
Series C (2022): $50M supported by Sands Capital, Northpond Ventures, Schooner Capital, and RA Capital Management
Debt (2022): $30M featuring Oxford Finance
Other Financing Round (2024): $48M backed by Sands Capital, Northpond Ventures, and RA Capital Management
Key Investors in SeLux DX
Sands Capital
Established in 1992, Sands Capital Management is a prominent investment firm headquartered in Arlington, Virginia, managing equity mutual funds and focusing on long-term growth opportunities in public and private markets.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, utilizing its internal think tank, TechAtlas, to guide strategic decisions.
Northpond Ventures
Northpond Ventures is a venture capital firm dedicated to advancing science and technology, focusing on breakthrough innovations that create significant, positive impacts on humanity.
What's next for SeLux DX?
With the successful closure of this major strategic investment, SeLux DX is poised to enter a new phase of commercial expansion and product development. The company is expected to prioritize the scaling of its diagnostic platform, focusing on broader clinical adoption and the integration of its technology into diverse healthcare settings. Furthermore, the capital will likely support the expansion of its internal research and development initiatives, ensuring that SeLux DX remains at the forefront of diagnostic innovation. As the company navigates this growth stage, its strategic focus will remain on enhancing diagnostic speed and accuracy, ultimately driving long-term value for stakeholders and improving the standard of care for patients worldwide.
See full SeLux DX company page
